4,537 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by International Assets Investment Management LLC

Posted by Defense World Staff on Apr 15th, 2023

International Assets Investment Management LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,537 shares of the medical research company’s stock, valued at approximately $307,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in shares of Natera during the 3rd quarter valued at about $5,083,000. Prelude Capital Management LLC bought a new position in shares of Natera during the 3rd quarter valued at about $806,000. Barclays PLC boosted its holdings in shares of Natera by 285.1% during the 3rd quarter. Barclays PLC now owns 106,211 shares of the medical research company’s stock valued at $4,655,000 after purchasing an additional 78,630 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Natera during the 3rd quarter valued at about $541,000. Finally, Maryland State Retirement & Pension System bought a new position in shares of Natera during the 4th quarter valued at about $308,000. Institutional investors own 93.81% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on NTRA. Credit Suisse Group increased their price objective on shares of Natera from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, March 1st. StockNews.com assumed coverage on shares of Natera in a report on Thursday, March 16th. They issued a “sell” rating for the company. Morgan Stanley increased their price target on shares of Natera from $70.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, March 2nd. Piper Sandler increased their price target on shares of Natera from $70.00 to $80.00 in a report on Friday, February 17th. Finally, Raymond James increased their price target on shares of Natera from $58.00 to $68.00 and gave the company an “outperform” rating in a report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $79.27.

Natera Stock Performance

Natera stock opened at $51.40 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.90 and a quick ratio of 3.79. Natera, Inc. has a 1-year low of $27.35 and a 1-year high of $59.75. The firm has a market capitalization of $5.82 billion, a P/E ratio of -9.23 and a beta of 1.21. The company’s 50-day moving average is $52.00 and its 200 day moving average is $45.02.

Natera (NASDAQ:NTRA – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The medical research company reported ($1.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.03. Natera had a negative net margin of 66.79% and a negative return on equity of 106.67%. The company had revenue of $217.30 million for the quarter, compared to analyst estimates of $215.50 million. During the same period in the prior year, the company posted ($1.48) EPS. The firm’s revenue for the quarter was up 25.6% on a year-over-year basis. Research analysts forecast that Natera, Inc. will post -4.16 EPS for the current year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 5,370 shares of the firm’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $223,177.20. Following the transaction, the chief executive officer now directly owns 103,779 shares of the company’s stock, valued at $4,313,055.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Steven Leonard Chapman sold 5,370 shares of the firm’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $223,177.20. Following the transaction, the chief executive officer now directly owns 103,779 shares of the company’s stock, valued at $4,313,055.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $54.02, for a total transaction of $270,100.00. Following the transaction, the insider now directly owns 524,746 shares in the company, valued at $28,346,778.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 177,468 shares of company stock valued at $8,592,009. 10.27% of the stock is currently owned by company insiders.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.